Aminosalicylates, thiopurines and methotrexate in inflammatory bowel disease: Is it possible to discontinue the treatment?

被引：3

作者：

Sedano Munoz, Rocio ^{[1
]}

Quera Pino, Rodrigo ^{[2
]}

Ibanez Lazo, Patricio ^{[2
]}

Figueroa Corona, Carolina ^{[2
]}

Flores Perez, Lilian ^{[2
]}

机构：

[1] Univ Chile, Hosp Clin, Serv Gastroenterol, Santiago, Chile

[2] Clin Las Condes, Serv Gastroenterol, Programa Enfermedad Inflamatoria Intestinal, Santiago, Chile

来源：

GASTROENTEROLOGIA Y HEPATOLOGIA | 2019年 / 42卷 / 05期

关键词：

Inflammatory bowel disease; Mesalazine; Thiopurines; Azathioprine; Mercaptopurine; Methotrexate; Biological therapy withdrawal; RANDOMIZED CONTROLLED-TRIAL; ACTIVE RECTAL INFLAMMATION; ULCERATIVE-COLITIS; FECAL CALPROTECTIN; CROHNS-DISEASE; LONG-TERM; MAINTENANCE TREATMENT; DOUBLE-BLIND; RISK-FACTORS; HISTOLOGICAL REMISSION;

D O I：

10.1016/j.gastrohep.2019.01.013

中图分类号：

R57 [消化系及腹部疾病];

学科分类号：

摘要：

The current goals of treatment in inflammatory bowel disease, both Crohn's disease and ulcerative colitis, are to achieve clinical, endoscopic and ideally histological remission and improve the quality of life of these patients. Current therapies are effective in achieving remission in most cases, but there is a lack of clear guidelines on their optimal duration. This review aims to evaluate the current evidence on the withdrawal of therapy with 5-aminosalicylates, thiopurines and methotrexate. We also aim to identify which specific group of patients, while in remission and in the absence of risk factors, may be able to discontinue therapy without a significant risk of relapse. (C) 2019 Elsevier Espana, S.L.U. All rights reserved.

引用

页码：339 / 347

页数：9

共 96 条

[1]

AKOBENG AK, 2016, COCHRANE DB SYST REV, V9, DOI DOI 10.1002/14651858.CD003715.PUB3

[2] Smoking habit and load influence age at diagnosis and disease extent in ulcerative colitis [J].

Aldhous, Marian C. ;

Drummond, Hazel E. ;

Anderson, Niall ;

Baneshi, M. Reza ;

Smith, Linda A. ;

Arnott, Ian D. R. ;

Satsangi, Jack .

AMERICAN JOURNAL OF GASTROENTEROLOGY, 2007, 102 (03) :589-597

[3]

Alfadhli AA, 2005, COCHRANE DB SYST REV, V1

[4]

Allez M, 2002, AM J GASTROENTEROL, V97, P947

[5] Clinical Trial: A Novel High-dose 1 g Mesalamine Suppository (Salofalk) Once Daily Is as Efficacious as a 500-mg Suppository Thrice Daily in Active Ulcerative Proctitis [J].

Andus, Tilo ;

Kocjan, Andreas ;

Mueser, Moritz ;

Baranovsky, Andrey ;

Mikhailova, Tatyana L. ;

Zvyagintseva, Tatyana D. ;

Dorofeyev, Andrey E. ;

Lozynskyy, Yurii S. ;

Cascorbi, Ingolf ;

Stolte, Manfred ;

Vieth, Michael ;

Dilger, Karin ;

Mohrbacher, Ralf ;

Greinwald, Roland .

INFLAMMATORY BOWEL DISEASES, 2010, 16 (11) :1947-1956

[6]

Annahazi A, 2015, GASTROENT RES PRACT, V2015, P1

[7]

[Anonymous], COCHRANE DATABASE SY, DOI DOI 10.1002/14651858

[8]

Ardizzone S, 1999, ALIMENT PHARM THERAP, V13, P373

[9] Randomised controlled trial of azathioprine and 5-aminosalicylic acid for treatment of steroid dependent ulcerative colitis [J].

Ardizzone, S ;

Maconi, G ;

Russo, A ;

Imbesi, V ;

Colombo, E ;

Porro, GB .

GUT, 2006, 55 (01) :47-53

[10] Limited Risks of Major Congenital Anomalies in Children of Mothers With IBD and Effects of Medications [J].

Ban, Lu ;

Tata, Laila Jal ;

Fiaschi, Linda ;

Card, Timothy .

GASTROENTEROLOGY, 2014, 146 (01) :76-84

← 1 2 3 4 5 6 7 8 9 10 →